GlassScriptPhysician profile
Lisa R Salinas
NPI 1356094353
$1,024.52
in general payments reported to CMS, 2019-2025
18 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $179 · 2023: $539 · 2024: $147 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $845.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $245.28 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Astrazeneca Pharmaceuticals LP | $158.97 | 2023-2025 | Breztri, Airsupra |
| Novo Nordisk INC | $129.37 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $70.23 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $68.25 | 2022-2023 | Shingrix, Arexvy |
| Abbott Laboratories | $56.39 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $42.06 | 2022-2023 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $34.12 | 2022 | |
| Janssen Pharmaceuticals, INC | $33.90 | 2022 | |
| Sanofi-Aventis U.S. LLC | $32.49 | 2023 | |
| Idorsia Pharmaceuticals US INC | $28.01 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $23.98 | 2022 | |
| Cranial Technologies, INC | $19.90 | 2023 | Doc Band |
| Boston Scientific Corporation | $19.78 | 2022 | |
| Abbvie INC. | $18.11 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $16.42 | 2023 | Intellis Adaptivestim |
| Lilly USA, LLC | $14.05 | 2024 | Zepbound |
| Pfizer INC. | $13.21 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Salinas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.